For neuroradiologists, the Signa Magnus 3T MRI system may offer enhanced visualization of the brain microstructure, microvasculature, and function.
Offering a combination of advanced gradient technology, deep-learning algorithms and short echo times, GE HealthCare is showcasing the new Signa Magnus 3T MRI at the International Society for Magnetic Resonance in Medicine (ISMRM) Annual Meeting in Singapore, Asia.
Featuring a gradient strength of 300 mT/m and slew rate of 750 T/m/s, the Signa Magnus is dedicated to head-only MRI imaging and reportedly provides enhanced imaging detail of the brain’s function, microstructure, and microvasculature, according to GE HealthCare.
Reportedly offering enhanced imaging detail of the brain’s function, microstructure, and microvasculature, the head-only 3T MRI system Signa Magnus provides higher b-value diffusion with short echo times, according to GE HealthCare, the manufacturer of the device. (Photo courtesy of GE HealthCare.)
In addition to deep-learning algorithms to bolster advanced imaging techniques, the company said another key attribute of the Signa Magnus MRI system is the capability to achieve higher b-value diffusion with short echo times.
"With Signa Magnus, we are not just exploring the possibility of providing the tool; we are setting new benchmarks in medical research and future clinical patient care.” said Kelly Londy, the chief executive officer of MR for GE HealthCare. “This innovation underscores our commitment to R&D and our collaborations with academia, pushing the boundaries of what's possible in MR imaging. The potential impact of Signa Magnus on patient outcomes and our understanding of the human brain is profound."
GE HealthCare noted that the Signa Magnus system is pending 510(k) clearance from the Food and Drug Administration (FDA).
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Published: June 21st 2025 | Updated: June 21st 2025Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.